Prof. Chunyi Hao 郝纯毅
Chief Physician, Professor
Soft Tissue and Retroperitoneal Tumor Center, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of primary and metastatic liver tumors, biliary and pancreatic tumors, and retroperitoneal tumors.
Dr. Hao earned a doctorate in oncology and graduated from Beijing Medical University in 1990. Trained under Professor Huang Xinfu, Dr. Hao serves as Director of the Soft Tissue and Retroperitoneal Tumor Center at Peking University Cancer Hospital. Dr. Hao helped author guidelines for colorectal cancer liver metastasis, primary liver cell carcinoma, and retroperitoneal soft tissue sarcoma.
Professional roles
- Chair, CSCO Pancreatic Cancer Expert Committee
- Vice Chair, CSCO Gastrointestinal Neuroendocrine Tumor Expert Committee
- Chair, China Medical Promotion Association Soft Tissue Tumor Expert Committee
- Secretary-General, China Medical Promotion Association Liver Cancer Expert Committee
Name order: in Chinese the family name comes first (Hao Chunyi). Papers usually list the name as Chunyi Hao or Hao C.
Selected publications
142 papers on PubMed matched by name and affiliation; 63 as first or senior author since 2016. Most recent first- or senior-author papers:
- Adv Ther, 2026 (senior author): Patient Characteristics and Treatment Patterns of Advanced Biliary Tract Cancer (BTC): A Chinese Physician Survey. PubMed 42804084
- Oncol Rep, 2025 (senior author): [Corrigendum] Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence. PubMed 40776751
- J Cancer Res Clin Oncol, 2025 (senior author): Bibliometric analysis of liposarcomas treatment from 2004 to 2023. PubMed 39856436
- Cancer Cell Int, 2024 (senior author): Integrated lipidomics and RNA-seq reveal prognostic biomarkers in well-differentiated and dedifferentiated retroperitoneal liposarcoma. PubMed 39696292
- World J Surg Oncol, 2024 (senior author): An additional gastrojejunostomy may reduce the incidence of moderate and severe delayed gastric emptying after distal segmental duodenectomy for gastrointestinal stromal tumors. PubMed 39543700
- Ther Adv Med Oncol, 2024 (senior author): Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma. PubMed 39281972
- Cancer Manag Res, 2024 (senior author): Prognostic Nutritional Index (PNI): A More Promising Nutritional Predictor for Patients Undergoing Surgery for Retroperitoneal Liposarcoma. PubMed 39157713
- BMC Cancer, 2024 (senior author): Optimizing surgical strategies for retroperitoneal liposarcoma: a comprehensive evaluation of standardized aggressive surgical policies. PubMed 39026264
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion